Does the Risk of New Metabolic Changes among Thyroid Cancer Survivors Depend upon Thyroid Function?
2Sackler Faculty of Medicine, Tel Aviv University
3Department of Cardiology, Tel Aviv Sourasky Medical Center
4School of Public Health, Sackler Faculty of Medicine, Tel Aviv University
5Oncology Division, Tel Aviv Sourasky Medical Center
6Department of Otolaryngology, Head & Neck and Maxillofacial Surgery, Tel Aviv Sourasky Medical Center
Background:
Various components of metabolic syndrome (MS) are known to significantly increase the risk of thyroid cancer (TC). Moreover, thyroid cancer survivors (TCS) are at increased risk of de novo components of MS. The role of thyroid function (TF) in this context has not yet been determined.
Aim:
To investigate changes in selected MSC and their association with TF during a two-year follow-up among TCS.
Methods:
This retrospective, nested case-control study used data from a single academic hospital. The one-hundred and fifteen participants had undergone total thyroidectomy and radioactive iodine treatment, followed by thyroid stimulating hormone supressive L-thyroxine therapy for two years due to differentiated TC.
Results:
The incidence of MS and its components increased in 51 TCS (cases) during a two-year follow-up. The other 64 TCS (controls) did not develop any new components of MS during the same period. The multivariable logistic regression analysis showed that TCS with a FT3/FT4 ratio greater than 0.22 (lower tertile) had a significantly increased risk of a new MSC (odds ratio 2.73, 95% confidence interval 1.14-6.57, p=0.025).
Conclusions:
This study demonstrated that an FT3/FT4 ratio greater than 0.22 is correlated with detrimental metabolic changes among TCS.
